Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Xilio Therapeutics, Inc. (XLO) had Non-Operating Income/Expense of $-1.48M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$8.08M |
|
$-15.84M |
|
-- |
|
$8.08M |
|
$22.45M |
|
$-14.37M |
|
|
Non-Operating Income/Expense |
$-1.48M |
$-15.84M |
|
$-15.84M |
|
$-15.84M |
|
$-15.84M |
|
$-15.84M |
|
$-15.84M |
|
$-14.37M |
|
$-13.98M |
|
96.45M |
|
96.45M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$123.72M |
|
$4.02M |
|
$10.10M |
|
$133.81M |
|
$53.26M |
|
-- |
|
$73.48M |
|
$126.74M |
|
$7.07M |
|
$7.07M |
|
$7.07M |
|
51.83M |
|
| Cash Flow Statement Financials | |
$14.50M |
|
$-0.42M |
|
$52.19M |
|
$57.07M |
|
$123.34M |
|
$66.27M |
|
$2.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-177.71% |
|
-177.71% |
|
-- |
|
-195.99% |
|
-195.99% |
|
$14.08M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
-- |
|
-- |
|
-224.13% |
|
-224.13% |
|
-11.84% |
|
-224.13% |
|
$0.14 |
|
$0.15 |
|
$0.15 |
|